Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivoBone, 2005
- Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone sizeCurrent Osteoporosis Reports, 2005
- Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal WomenNew England Journal of Medicine, 2004
- The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal OsteoporosisNew England Journal of Medicine, 2003
- Identification of a Novel Phosphonocarboxylate Inhibitor of Rab Geranylgeranyl Transferase That Specifically Prevents Rab Prenylation in Osteoclasts and MacrophagesJournal of Biological Chemistry, 2001
- Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic womenBone, 2000
- Etidronate inhibits human osteoblast apoptosis by inhibition of pro-apoptotic factor(s) produced by activated T cellsJournal of Laboratory and Clinical Medicine, 2000
- Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.Journal of Clinical Investigation, 1997
- Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized ratsBone, 1995
- Alendronate increases skeletal mass of growing rats during unloading by inhibiting resorption of calcified cartilageJournal of Bone and Mineral Research, 1994